O'Donoghue JA, et al. - Researchers performed this study evaluating ⁸⁹Zr-trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive esophagogastric adenocarcinoma (EGA). Here, they estimated the safety, pharmacokinetics, biodistribution, and dosimetry ⁸⁹Zr-trastuzumab. ⁸⁹Zr-trastuzumab imaging tracer proved safe and provided high-quality images in these patients, with an optimal imaging time of 5–8 d after injection.